237 related articles for article (PubMed ID: 29489079)
1. [Formulation of new generation drug delivery system for dry powder inhalation.].
Chvatal A; Szabo B; Szabo-Revesz P; Ambrus R
Acta Pharm Hung; 2016; 86(3):75-83. PubMed ID: 29489079
[TBL] [Abstract][Full Text] [Related]
2. Formulation strategy and use of excipients in pulmonary drug delivery.
Pilcer G; Amighi K
Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
[TBL] [Abstract][Full Text] [Related]
3. Alternative carriers in dry powder inhaler formulations.
Rahimpour Y; Kouhsoltani M; Hamishehkar H
Drug Discov Today; 2014 May; 19(5):618-26. PubMed ID: 24269834
[TBL] [Abstract][Full Text] [Related]
4. Influence of carrier on the performance of dry powder inhalers.
Saint-Lorant G; Leterme P; Gayot A; Flament MP
Int J Pharm; 2007 Apr; 334(1-2):85-91. PubMed ID: 17113733
[TBL] [Abstract][Full Text] [Related]
5. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis.
Young PM; Salama RO; Zhu B; Phillips G; Crapper J; Chan HK; Traini D
Drug Dev Ind Pharm; 2015 May; 41(5):859-65. PubMed ID: 24811055
[TBL] [Abstract][Full Text] [Related]
6. Effect of carrier morphology and surface characteristics on the development of respirable PLGA microcapsules for sustained-release pulmonary delivery of insulin.
Hamishehkar H; Emami J; Najafabadi AR; Gilani K; Minaiyan M; Mahdavi H; Nokhodchi A
Int J Pharm; 2010 Apr; 389(1-2):74-85. PubMed ID: 20085803
[TBL] [Abstract][Full Text] [Related]
7. The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules.
Sou T; Kaminskas LM; Nguyen TH; Carlberg R; McIntosh MP; Morton DA
Eur J Pharm Biopharm; 2013 Feb; 83(2):234-43. PubMed ID: 23183447
[TBL] [Abstract][Full Text] [Related]
8. Dry powders for oral inhalation free of lactose carrier particles.
Healy AM; Amaro MI; Paluch KJ; Tajber L
Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
[TBL] [Abstract][Full Text] [Related]
9. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
10. Dry-powder formulations of non-covalent protein complexes with linear or miktoarm copolymers for pulmonary delivery.
Nieto-Orellana A; Coghlan D; Rothery M; Falcone FH; Bosquillon C; Childerhouse N; Mantovani G; Stolnik S
Int J Pharm; 2018 Apr; 540(1-2):78-88. PubMed ID: 29425761
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Evaluation of Surface Modified Lactose Particles for Improved Performance of Fluticasone Propionate Dry Powder Inhaler.
Singh DJ; Jain RR; Soni PS; Abdul S; Darshana H; Gaikwad RV; Menon MD
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):254-67. PubMed ID: 25517187
[TBL] [Abstract][Full Text] [Related]
12. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants.
Cheow WS; Ng ML; Kho K; Hadinoto K
Int J Pharm; 2011 Feb; 404(1-2):289-300. PubMed ID: 21093560
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the cohesion-adhesion balance approach to colloidal probe atomic force microscopy and the measurement of Hansen partial solubility parameters by inverse gas chromatography for the prediction of dry powder inhalation performance.
Jones MD; Buckton G
Int J Pharm; 2016 Jul; 509(1-2):419-430. PubMed ID: 27265314
[TBL] [Abstract][Full Text] [Related]
14. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
15. The role of the solid state and physical properties of the carrier in adhesive mixtures for lung delivery.
Della Bella A; Salomi E; Buttini F; Bettini R
Expert Opin Drug Deliv; 2018 Jul; 15(7):665-674. PubMed ID: 28829232
[TBL] [Abstract][Full Text] [Related]
16. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
17. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
18. New aspects of developing a dry powder inhalation formulation applying the quality-by-design approach.
Pallagi E; Karimi K; Ambrus R; Szabó-Révész P; Csóka I
Int J Pharm; 2016 Sep; 511(1):151-160. PubMed ID: 27386791
[TBL] [Abstract][Full Text] [Related]
19. [Stability testing of meloxicam-containing microcomposites for inhalation].
Pomázi A; Ambrus R; Szabóné Révész P
Acta Pharm Hung; 2014; 84(2):55-62. PubMed ID: 25167700
[TBL] [Abstract][Full Text] [Related]
20. Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Int J Pharm; 2012 May; 428(1-2):103-13. PubMed ID: 22414388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
